Cargando…

Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma

For patients with platinum-resistant lung adenocarcinoma (LUAD), the exploration of new effective drug candidates is urgently needed. Fibroblast growth factor receptors (FGFRs) have been identified as promising targets for LUAD therapy. The purpose of this study was to determine the exact role of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Xiuqin, Xin, Ming, Xu, Juanjuan, Xiang, Xindong, Li, Xuan, Jiao, Yuhan, Wang, Lulin, Jiang, Jingjing, Pang, Feng, Zhang, Xianzhen, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428205/ https://www.ncbi.nlm.nih.gov/pubmed/36042213 http://dx.doi.org/10.1038/s41419-022-05201-0

Ejemplares similares

Autophagy Inhibition Enhances the Anti-Tumor Activity of Methylseleninic Acid in Cisplatin-Resistance Human Lung Adenocarcinoma Cells
por: Xin, Ming, et al.
Publicado: (2022)

Polyphyllin II induced apoptosis of NSCLC cells by inhibiting autophagy through the mTOR pathway
por: Jiao, Yuhan, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
por: Saridogan, Turcin, et al.
Publicado: (2023)

Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study
por: Ziegler, Bernhard, et al.
Publicado: (2021)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

FGFR2 amplification in colorectal adenocarcinoma
por: Carter, Jamal H., et al.
Publicado: (2017)

Establishment and validation of the autophagy-related ceRNA network in irreversible pulpitis
por: Wang, Ye, et al.
Publicado: (2023)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Expression of autophagy-associated proteins in rat dental irreversible pulpitis
por: Qi, Shengcai, et al.
Publicado: (2019)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Drug-sensitive FGFR3 mutations in lung adenocarcinoma
por: Chandrani, P., et al.
Publicado: (2017)

Enzymatic Redox Properties and Cytotoxicity of Irreversible Nitroaromatic Thioredoxin Reductase Inhibitors in Mammalian Cells
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2023)

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
por: Bahleda, R., et al.
Publicado: (2020)

Role of FGFR2c and Its PKCε Downstream Signaling in the Control of EMT and Autophagy in Pancreatic Ductal Adenocarcinoma Cells
por: Ranieri, Danilo, et al.
Publicado: (2021)

Cholesterol oxidase from Bordetella species promotes irreversible cell apoptosis in lung adenocarcinoma by cholesterol oxidation
por: Liu, J, et al.
Publicado: (2014)

Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation
por: Papoulas, Michail, et al.
Publicado: (2018)

Role of imaging in the applicability of irreversible electroporation for the management of pancreatic adenocarcinoma
por: da Silva, Thiago Pereira Fernandes, et al.
Publicado: (2023)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
por: Luan, Wenqing, et al.
Publicado: (2019)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model
por: Philips, Prejesh, et al.
Publicado: (2015)

IRREVERSIBLE ELECTROPORATION TREATMENT OF PANCREATIC ADENOCARCINOMA – A FIRST IN NORTHERN IRELAND
por: Wilson, Miss R, et al.
Publicado: (2019)

Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers
por: Porębska, Natalia, et al.
Publicado: (2021)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Aminochrome Induces Irreversible Mitochondrial Dysfunction by Inducing Autophagy Dysfunction in Parkinson's Disease
por: Segura-Aguilar, Juan, et al.
Publicado: (2018)

Irreversible
Publicado: (2009)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

The Aberrant Expression of the Mesenchymal Variant of FGFR2 in the Epithelial Context Inhibits Autophagy
por: Nanni, Monica, et al.
Publicado: (2019)

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
por: Jiang, Yongdong, et al.
Publicado: (2015)

Methotrexate Cytotoxicity as Related to Irreversible S Phase Arrest in Mouse L1210 Leukemia Cells
por: Tsurusawa, Masahito, et al.
Publicado: (1990)

Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome
por: Trueba-Arguiñarena, Francisco Javier, et al.
Publicado: (2015)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Autophagy-independent enhancing effects of Beclin 1 on cytotoxicity of ovarian cancer cells mediated by proteasome inhibitors
por: Liu, Chuan, et al.
Publicado: (2012)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors
por: Zhang, Nana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nehselp7c364dfhpq9fbvmmrp9